Navigation Links
Experimental Drug Fights Bone Marrow Cancers
Date:12/9/2008

There are currently no FDA-approved treatments for these malignancies

TUESDAY, Dec. 9 (HealthDay News) -- An experimental drug called CYT387 blocks an enzyme that causes bone marrow cancers called myeloproliferative disorders (MPDs), according to U.S. researchers who conducted tests in mice and human cells.

The findings were to be presented Tuesday at the annual meeting of the American Society of Hematology, in San Francisco.

The researchers, from Oregon Health & Science University's Knight Cancer Institute, found that CYT387 was "very effective" against a specific type of cancer cell driven by an enzyme mutation called JAK2-V617F. The drug binds to the V617F mutation in the JAK2 enzyme.

"In the mouse model, the drug blocked JAK2-V617F, normalized blood counts and reduced enlarged spleens back to a normal size. It is a very promising compound," researcher Dr. Thomas Bumm said in a university news release.

There are no U.S. Food and Drug Administration-approved targeted treatments for the "big three" MPDs -- polycythemia vera, essential thrombocythemia and primary myelofibrosis.

"Based on the efficacy we demonstrated in the mouse model, there is a good chance that CYT387 will enter clinical trials as early as 2009," principal investigator Dr. Michael Deininger, head of the hematological malignancies program, said in the news release.

The study was funded by Cytopia Research Pty Ltd. of Australia, which makes the drug.

More information

The Leukemia and Lymphoma Society has more about MPDs.



-- Robert Preidt



SOURCE: Oregon Health & Science University, news release, Dec. 9, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Page: 1

Related medicine news :

1. Experimental Vaginal Gel Doesnt Ward Off HIV
2. Experimental TB drug explodes bacteria from the inside out
3. Cephalon and ImmuPharma Sign a $15 million Option Agreement for Late- Stage Experimental Lupus Medication
4. Phase II Trial of Experimental Anti-Coagulant Reports Safety and Outcomes Data
5. Experimental Apartment in Beijing Achieves 99% Purity of Indoor Air
6. Experimental Drug Fights Multiple Sclerosis Activity
7. Experimental Therapy Beats Back One Patients Melanoma
8. Experimental agent blocks prostate cancer in animal study
9. Experimental Drug Eases Symptoms of Mild Alzheimers
10. Experimental Blood Substitutes Unsafe, Study Finds
11. Honda to Showcase Experimental Walking Assist Device
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Experimental Drug Fights Bone Marrow Cancers
(Date:12/7/2016)... ... December 07, 2016 , ... Children exposed to secondhand marijuana ... the Icahn School of Medicine at Mount Sinai has found. The study was ... children are exposed to secondhand marijuana smoke, measurable amounts of primary metabolite of ...
(Date:12/7/2016)... ... December 07, 2016 , ... Wavelink, ... Device Remote Control through a new partnership with Splashtop Inc. This remote control ... mobile solutions to help businesses maximize their uptime and productivity. , Wavelink offers ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... S.L. (“Presence”) for a purchase price of approximately $17.4 million (net of ... annual revenue is approximately $13.2 million. Headquartered in Barcelona, Spain, Presence is ...
(Date:12/7/2016)... Yorba Linda, Ca (PRWEB) , ... December 07, 2016 , ... ... to attain that funding is with useful, properly analyzed data. The team at Beckman ... generation to address the 'need for speed' and the need to operate in a ...
(Date:12/7/2016)... ... 2016 , ... A quote from Dr. Edward Hallowell, host of CRN International’s ... offer a rare glimpse into the mind of those people with ADHD. , Dr. ... author, has described people with ADHD as having “Ferrari engines for a brain, with ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016 Eli Lilly and ... the neoMONARCH study of abemaciclib, a cyclin-dependent kinase (CDK) ... of reducing expression of Ki67, a biomarker of cell ... the Phase 2 trial presented during the official press ... (SABCS) evaluated abemaciclib, both alone or in combination with ...
(Date:12/7/2016)... Global Cervical Dysplasia Market: Scope and ... dysplasia market analyzes the current and future prospects ... executive summary, including a market snapshot that provides ... The research is a combination of primary and ... our research efforts along with information collected from ...
(Date:12/7/2016)... REPORT OBJECTIVES The report ... intelligence on a market segment, based on geography. ... in the report. The primary objectives of this ... intelligence through detailed segmentation, 2) market size and ... developments, market situation, trends, 3) detailed analysis of ...
Breaking Medicine Technology: